Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boostrix, Adacel Seek Approval Based On Studies Comparing Infants And Adolescents

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA vaccine advisory committee will meet March 15 to review the Tdap boosters from GlaxoSmithKline and Sanofi Pasteur. The products are intended to address the rising incidence of pertussis. Applications rely on trial design recommended by the committee in 1997.

You may also be interested in...



Boostrix, Adacel Tdap Boosters Are Effective, FDA Advisory Committee Says

Advisory panel members urge postmarket monitoring for GSK and Sanofi Pasteur boosters in patients who received full series of acellular pertussis vaccines as children, given that the studies were conducted in patients who received whole-cell vaccines. Committee endorses “effectiveness,” but offers no opinion on “efficacy.”

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel